List view / Grid view
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The committee agreed the combination offers life extending benefit compared to vemurafenib alone, however compared to alternative treatments it is too expensive. About 1,000 people would have been eligible each year...
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The combination of Galenica's Vifor Pharma business with Relypsa will create a significant player in cardio-renal care in the US and further strength...
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Aeterna Zentaris signed an exclusive license agreement with affiliates of Orient EuroPharma for its lead anti-cancer compound, zoptrex, for the initial...
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Gelesis, a biotechnology company focused on developing products to safely induce weight loss and improve glycaemic control, have appointed David Pass, PhD as Chief Operating Officer...
5 September 2016 | By Eppendorf
Within the EU Research and Innovation program Horizon 2020 the European Union is now funding the TECHNOBEAT research project with almost 6 million Euro...
5 September 2016 | By Niamh Louise Marriott, Digital Content Producer
n study 309, the pivotal phase III trial on which the indication approval was based, eribulin demonstrated a significant survival advantage in advanced liposarcoma; patients treated with eribulin compared to those treated with dacarbazine, a longstanding, established and internationally accepted treatment option, benefited from a median 7.2 month increase in…
5 September 2016 | By Niamh Louise Marriott, Digital Content Producer
RM radiation doses were significantly higher in the patients who did not receive predosing, indicating that pre-dosing with lilotomab has a protective...
5 September 2016 | By Biopharma Group
Fluid processing requirements are becoming ever more stringent, and so high pressure homogenisation is increasingly surfacing as a solution to meeting these needs...
5 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The two-stage clinical trial studied the safety, tolerability, and efficacy of intra-nasally applied exeporfinium chloride gels. Part 1 yielded safety data in eight volunteers and allowed progression to Part 2 in 48 healthy volunteers with colonised nasal Staphylococcus aureus (SA) bacteria. Part 2 was double-blinded, placebo controlled, and investigated two…
2 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The approval is based on data from the phase 3b clinical trial, which examined the efficacy and safety of liraglutide versus placebo as an add-on to existing diabetes medication, to improve glycaemic control...
2 September 2016 | By CI Precision
Aesica Pharmaceuticals is implementing CI Precision’s MES solution (Ci-DMS) in their dispensing areas to remove labour-intensive manual processes, improve data integrity and integrate with their SAP ERP system.
2 September 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE has today issued draft final guidance recommending radium-223 dichloride (Xofigo, Bayer) as an option for treating prostate cancer...
2 September 2016 | By PerkinElmer Inc
ChemDraw software moves to the cloud for enhanced collaboration among chemists and biologists...
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Roche’s study for tecentriq (atezolizumab) met its co-primary endpoints and showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared with docetaxel chemotherapy in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on or after treatment with platinum-based chemotherapy. Adverse events…
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The FDA approval is based on analytical, nonclinical, and clinical data confirming that Erelzi is highly similar to the US-licensed reference product. Clinical studies included four comparative pharmacokinetic (PK) studies in 216 healthy volunteers and a confirmatory efficacy and safety similarity study in 531 patients with chronic plaque psoriasis...
